OPRX vs. EVH, NXTT, YEXT, TIXT, RSKD, IIIV, NRDS, WLDN, PRSU, and PSFE
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Evolent Health (EVH), Next Technology (NXTT), Yext (YEXT), TELUS Digital (TIXT), Riskified (RSKD), i3 Verticals (IIIV), NerdWallet (NRDS), Willdan Group (WLDN), Pursuit Attractions & Hospitality (PRSU), and Paysafe (PSFE). These companies are all part of the "business services" industry.
OptimizeRx vs.
Evolent Health (NYSE:EVH) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
Evolent Health has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Evolent Health received 415 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 74.90% of users gave Evolent Health an outperform vote while only 65.08% of users gave OptimizeRx an outperform vote.
Evolent Health presently has a consensus price target of $17.79, indicating a potential upside of 100.06%. OptimizeRx has a consensus price target of $10.81, indicating a potential downside of 30.15%. Given Evolent Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evolent Health is more favorable than OptimizeRx.
OptimizeRx has lower revenue, but higher earnings than Evolent Health. OptimizeRx is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.
Evolent Health has a net margin of -2.41% compared to OptimizeRx's net margin of -27.41%. Evolent Health's return on equity of 5.73% beat OptimizeRx's return on equity.
76.5% of OptimizeRx shares are held by institutional investors. 1.4% of Evolent Health shares are held by company insiders. Comparatively, 5.6% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, OptimizeRx had 3 more articles in the media than Evolent Health. MarketBeat recorded 6 mentions for OptimizeRx and 3 mentions for Evolent Health. OptimizeRx's average media sentiment score of 0.92 beat Evolent Health's score of 0.86 indicating that OptimizeRx is being referred to more favorably in the news media.
Summary
Evolent Health beats OptimizeRx on 11 of the 19 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
This page (NASDAQ:OPRX) was last updated on 6/11/2025 by MarketBeat.com Staff
